CALGB 80405英文原版_ASCO_2014.ppt概要1.pptx

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma of the colon or rectum ;National Clinical Trials Network; CALGB/SWOG 80405:  FINAL DESIGN; COLORECTAL CANCER IN 2004  IS THERE AN OPTIMAL 1ST LINE TREATMENT ?; 2004: A lot can happen in 10 years; CALGB / SWOG 80405:  WHY DID IT TAKE TEN YEARS?;CALGB/SWOG 80405: Eligibility Criteria;CALGB/SWOG 80405: Endpoints;CALGB/SWOG 80405: Statistics;CALGB/SWOG 80405: Statistics;Presented by:; RESULTS 11th Interim Analysis D Niedzwiecki ;CALGB/SWOG 80405: Overall Survival ;CALGB/SWOG 80405: Progression-Free Survival(Investigator Determined);;CALGB/SWOG 80405: Overall SurvivalFOLFOX Treated ;CALGB/SWOG 80405: Overall SurvivalFOLFIRI Treated; Patients Rendered Disease-FreeOverall Survival; Grade 3-4 Toxicities ;Presented by:; 80405: Data Pending ; Quality of Life and Symptoms;Presented by:; “Expanded RAS”; Correlative Studies Tumor / Plasma / Serum 44000 samples; 80405: Upcoming Presentations ;CALGB/SWOG 80405: Conclusions;CALGB/SWOG 80405: Conclusions;CALGB/SWOG 80405: Conclusions;J Clin Oncol, 1992; TAKE HOME MESSAGE; Clarify standard of care Answer question that Industry might not ask Of practical importance to oncologists Accessible across US and Canada Take as much time as is necessary Broad range of correlative research; ACKNOWLEDGEMENTS / THANKS Collaborators;ACKNOWLEDGEMENT / THANK YOU;;